Humanized Anti-Human MS4A1 Therapeutic Antibody (BLX-301)
BLX-301 is a humanized anti-CD20 candidate incorporating the optimized glycosylation benefits of the LEX System, and currently expects that the first indication targeted for development will be non-Hodgkin's B-cell lymphoma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-1649CL |
| Pricing | Inquiry |
| Type | Humanized antibody |
| Host | Human |
| Target | CD20 |